

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 DECEMBER 2024 ERRATA

- (1) This Erratum corrects the price for DABIGATRAN (Pradaxa) items 9319L and 9323Q in the 1 December 2024 Schedule. The price of these items should not have changed from 1 November 2024.

General Pharmaceutical Benefits

▪ DABIGATRAN

Note No increase in the maximum quantity or number of units may be authorised.

Note No increase in the maximum number of repeats may be authorised.

Authority required (STREAMLINED)

4369

Prevention of venous thromboembolism

Treatment criteria:

- Patient must be undergoing total hip replacement.

Clinical criteria:

- Patient must require up to 20 days supply to complete a course of treatment.

dabigatran etexilate 75 mg capsule, 10

9318K	Max. Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
NP	2	1	..	*35.69	31.60	Pradaxa [BY]

dabigatran etexilate 110 mg capsule, 10

9319L	Max. Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
NP	2	1	..	*26.79	28.24	Pradaxa [BY]

▪ DABIGATRAN

Note No increase in the maximum quantity or number of units may be authorised.

Note No increase in the maximum number of repeats may be authorised.

Authority required (STREAMLINED)

4381

Prevention of venous thromboembolism

Treatment criteria:

- Patient must be undergoing total knee replacement.

Clinical criteria:

- Patient must require up to 10 days of therapy.

dabigatran etexilate 75 mg capsule, 10

9322P	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
NP	2	*35.69	31.60	Pradaxa [BY]

dabigatran etexilate 110 mg capsule, 10

9323Q	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
NP	2	*26.79	28.24	Pradaxa [BY]